Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.

NCT04335162

Conditions

1. COVID
2. Acute Coronary Syndrome
3. Myocardial Infarction
4. Myocarditis
5. Venous Thromboembolism
6. Deep Vein Thrombosis
7. Pulmonary Embolism

MeSH:Pulmonary Embolism Myocardial Infarction Thrombosis Acute Coronary Syndrome Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis Myocarditis

HPO:Deep venous thrombosis Myocardial infarction Myocarditis Pulmonary embolism Thromboembolism Venous thrombosis

The aim of this study is to verify if patients admitted to hospital in a medical division and in the intensive care unit for a COVID-19 infection are at higher risk of developing a VTE complication and if they actually present an increased hypercoagulable state.

NCT04359212

Conditions

1. COVID-19 Disease
2. Thromboembolism, Venous

Interventions

1. Drug: thromboprophylaxis with low-molecular-weight heparin or fondaparinux

MeSH:Thromboembolism Venous Thromboembolism

HPO:Thromboembolism

The understanding of haemostasis and inflammation cross-talk has gained considerable knowledge during the past decade in the field of arterial and venous thrombosis. Complex and delicately balanced interaction between coagulation and inflammation involve all cellular and humoral components. Elements of the coagulation system such as activated thrombin, fibrinogen or factor Xa may increase inflammation by promoting the production of pro-inflammatory cytokines, chemokines, growth factors and adhesion molecules that lead to a procoagulant state amplifying the pathological process. Recent evidence supports inflammation as a common pathogenic contributor to both arterial and venous thrombosis, giving rise to the concept of inflammation-induced thrombosis. Patients with infection of COVID-19 and severe pneumoniae seem to have higher risk of thromboembolism. Very few data are available regarding the biological disorders of coagulation in these patients. Th purpose of this project is to analyze hemostasis and coagulation of patients with infection of COVID-19 and severe pneumonia.

NCT04366752

Conditions

1. COVID-19
2. Pneumonia
3. ARDS
4. Hemostasis
5. Coagulation

Interventions

1. Other: venous ultrasound
2. Other: blood sample

MeSH:Pneumonia Thromboembolism

HPO:Pneumonia Thromboembolism

This study is being conducted to assess the effectiveness of intermediate versus prophylactic doses of anticoagulation (blood thinners) in patients critically ill with COVID-19 in the intensive care units (ICUs) throughout the hospital. Anticoagulation is part of the patient's usual standard of care but determining the dose of anticoagulation is based on physician preference. The investigators are conducting this study (a randomized trial with adaptive design employing cluster randomization) with the support of all of the ICUs to collect data in order to determine what should be the standard of care in terms of anticoagulation in these critically ill patients. The patients care will not be altered other than the choice of anticoagulation (both approved and used throughout the hospital as standard of care) based on the ICU bed they are assigned. Patient data will be collected until discharge.

NCT04367831

Conditions

1. COVID-19
2. Venous Thromboses
3. Arterial Thrombosis

Interventions

1. Drug: Enoxaparin Prophylactic Dose
2. Drug: Heparin Infusion
3. Drug: Heparin SC
4. Drug: Enoxaparin/Lovenox Intermediate Dose

MeSH:Thrombosis Thromboembolism Venous Thrombosis

HPO:Deep venous thrombosis Thromboembolism Venous thrombosis

Worldwide observational studies indicate a significant prothrombogenic effect associated with SARS-CoV-2 infection with a high incidence of venous thromboembolism (VTE), notably life-threatening pulmonary embolism. According to recommendations for acute medical illnesses, all COVID-19 hospitalized patients should be given VTE prophylaxis such as a low molecular weight heparin (LMWH). A standard prophylactic dose (eg. Enoxaparin 4000IU once daily) could be insufficient in obese patients and VTE has been reported in patients treated with a standard prophylactic dose. In COVID-19 patients, guidelines from several international societies confirm the existence of an hypercoagulability and the importance of thromboprophylaxis but the "optimal dose is unknown" and comparative studies are needed. In view of these elements, carrying out a trial comparing various therapeutic strategies for the prevention of VTE in hospitalized patients with COVID-19 constitutes a health emergency. Thus, we hypothesize that an increased prophylactic dose of weight-adjusted LMWH would be greater than a lower prophylactic dose of LMWH to reduce the risk of life-threatening VTE in hospitalized patients. The benefit-risk balance of this increase dose will be carefully evaluated because of bleeding complications favored by possible renal / hepatic dysfunctions, drug interactions or invasive procedures in COVID-19 patients. This multicenter randomized (1:1) open-label controlled trial will randomize hospitalized adults with COVID-19 infection to weight-adjusted prophylactic dose vs. lower prophylactic dose of LMWH.

NCT04373707

Conditions

1. COVID
2. Thrombosis
3. Pulmonary Embolism
4. Deep Vein Thrombosis

Interventions

1. Drug: Enoxaparin
2. Drug: Enoxaparin

MeSH:Pulmonary Embolism Thrombosis Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis

HPO:Deep venous thrombosis Pulmonary embolism Thromboembolism Venous thrombosis

Severe COVID-19 patients at a high risk of venous thromboembolism. We studied patients in 2 intensive care units of university hospitals in Barcelona and Badalona, Spain. We performed a cut-off screening of deep venous thrombosis (DVT) with bilateral duplex ultrasound to 230 patients.

NCT04374617

Conditions

1. COVID-19
2. Critical Illness
3. Venous Thromboembolism
4. Venous Thromboses
5. Venous Thromboses, Deep
6. Venous Thrombosis Pulmonary
7. Pulmonary Embolism
8. Pulmonary Embolism and Thrombosis
9. Sars-CoV2
10. SARS-CoV Infection

Interventions

1. Diagnostic Test: Duplex ultrasound and Computed Tomography Angiography

MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Pulmonary Embolism Thrombosis Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis Embolism and Thrombosis Critical Illness

HPO:Deep venous thrombosis Pulmonary embolism Thromboembolism Venous thrombosis

The understanding of haemostasis and inflammation cross-talk has gained considerable knowledge during the past decade in the field of arterial and venous thrombosis. Complex and delicately balanced interaction between coagulation and inflammation involve all cellular and humoral components. Elements of the coagulation system such as activated thrombin, fibrinogen or factor Xa may increase inflammation by promoting the production of proinflammatory cytokines, chemokines, growth factors and adhesion molecules that lead to a procoagulant state amplifying the pathological process. Recent evidence supports inflammation as a common pathogenic contributor to both arterial and venous thrombosis, giving rise to the concept of inflammation induced thrombosis. Patients with infection of COVID-19 and severe pneumoniae seem to have higher risk of thromboembolism. The purpose of this project is to analyze hemostasis and coagulation of every hospitalized patient with infection of COVID-19. Blood sample for coagulation and hemostasis analysis will be collected on every patient hospitalized in Amiens hospital for COVID-19 infection. Thrombin time, factors V and II, fibrin/fibrinogen degradation products, antithrombin will be assessed every week. Anticardiolipin, anti-beta2 glycoprotein I and anti-annexin A2 antibodies IgG and IgM at day of admission and at fourth week after admission will be assessed. SARS-CoV2 viral load and serodiagnosis will be performed at the same time. At the same time venous ultrasound to diagnose thrombosis will be performed.

NCT04377490

Conditions

1. COVID-19
2. Hemostasis
3. Coagulation

Interventions

1. Other: venous ultrasound
2. Biological: blood sample

MeSH:Thromboembolism

HPO:Thromboembolism

The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.

NCT04394000

Conditions

1. COVID19
2. Thromboembolism

Interventions

1. Other: thromboprofylaxis protocol
2. Other: standard protocol

MeSH:Thromboembolism

HPO:Thromboembolism

The purpose of this study is to investigate the prevalence of venous thromboembolism in a regional health care system (Region Östergötland, Sweden) before and during the SARS-COV-2 pandemic. In a retrospective observational study, we will review patient data, diagnostic data and treatment data over a three-month period since the onset of the SARS-COV-2 pandemic. This data will be compared with data from the corresponding time frame during the years 2015 to 2019.

NCT04400877

Conditions

1. COVID-19
2. Venous Thromboembolism
3. Pulmonary Embolism
4. Deep Vein Thrombosis
5. SARS-CoV 2

Interventions

1. Diagnostic Test: Diagnostic examination for venous thromboembolism

MeSH:Pulmonary Embolism Thrombosis Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis

HPO:Deep venous thrombosis Pulmonary embolism Thromboembolism Venous thrombosis

The main objective of this study is to describe the incidence of thromboembolic events in a population of patients hospitalized in intensive care units in France for severe COVID-19. The secondary objective of this study is to describe the evolution of hemostasis parameters during the first two weeks of intensive care hospitalization and to evaluate the influence of different anticoagulation regimens on these parameters and on the incidence of thromboembolic events

NCT04405869

Conditions

1. Pulmonary Thromboembolism

MeSH:Pulmonary Embolism Thromboembolism

HPO:Pulmonary embolism Thromboembolism

This is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events.

NCT04409834

Conditions

1. COVID-19
2. Venous Thromboembolism
3. Arterial Thrombosis

Interventions

1. Drug: Unfractionated Heparin IV
2. Drug: Enoxaparin 1 mg/kg
3. Drug: Clopidogrel
4. Drug: Unfractionated heparin SC
5. Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution

MeSH:Thrombosis Thromboembolism Venous Thromboembolism

HPO:Thromboembolism

The aims of the study are to to associate anticoagulation (AC) regime with outcome in critically ill patients with Covid-19. This will be done by describe baseline characteristics and comorbidities before hospital admission, level of organ support and dose of AC treatment and associate this with 28 days survival, survival outside ICU, thromboembolic event and bleeding complications.

NCT04412304

Conditions

1. Covid-19
2. Thromboembolic Events
3. Bleeding

Interventions

1. Drug: Dose of Tinzaparin or Dalteparin

MeSH:Thromboembolism

HPO:Thromboembolism

Covid-19 mainly affects the respiratory system. Multiple organ dysfunction and a particularly progressive respiratory insufficiency along with a widespread coagulopathy presumed to be due to infection-associated inflammation and the resulting cytokine storm, are strongly associated with high mortality rates. In this study, the association between thrombosis risk and clinical presentation of Covid-19 is investigated.

NCT04423315

Conditions

1. Corona Virus Infection
2. Thromboembolic Disease

MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia Thrombosis Thromboembolism

HPO:Pneumonia Thromboembolism

Published papers evaluating coagulopathy on COVID-19 patients indicate a higher incidence of thromboembolic events, sometimes, as high as 20%. Such events increase ICU admissions and are associated with death. Considering the importance of thromboembolic events concurring to deteriorate clinical state, we propose to conduct a parallel pragmatic open-label randomized controlled trial to determine the effect of therapeutic anticoagulation compared to standard care in hospitalized patients with COVID-19 and with low oxygen saturation.

NCT04444700

Conditions

1. COVID
2. Coronavirus Infection
3. Severe Acute Respiratory Syndrome
4. Thromboembolism, Venous
5. Anticoagulants and Bleeding Disorders

Interventions

1. Drug: Therapeutic anticoagulation

MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Thromboembolism Hemostatic Disorders Venous Thromboembolism Blood Coagulation Disorders

HPO:Abnormality of coagulation Abnormality of the coagulation cascade Thromboembolism